This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Besifovir

Ildong Pharmaceutical Co., Ltd.

Drug Names(s): ANA380, LB80380

Description: ANA380 is an oral prodrug of ANA317, a nucleotide analog for the treatment of chronic HBV infection.

Deal Structure: Anadys and LG
In April 2004, Anadys entered into an agreement with LG Life Sciences (LGLS) for the joint development and potential commercialization of ANA380. Under the terms of the agreement, Anadys and LGLS were to jointly conduct and equally fund the global clinical development of ANA380 for HBV and LGLS granted to Anadys an exclusive license to commercialize ANA380 as a therapy for chronic HBV in North America, Europe, Japan and all other countries in the world other than China, Korea, India and countries in Southeast Asia.

In August 2007, Anadys discontinued development of ANA380 and all rights to the compound were returned to LGLS.

IlDong and LG
In September 2012, IlDong Pharmaceutical announced that they have signed a licensing agreement for the pharmaceutical treatment of hepatitis B drug, Besifovir, with LG Life Sciences. With this partnership, IlDong will be responsible for any procedures and approvals, production, and Phase III studies...See full deal structure in Biomedtracker

Partners: LG Life Sciences Ltd.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug